{"entity":{"id":"nct06196736","kind":"trial","name":"A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer","aka":[],"tldr":"A phase 3 trial of 9MW2821 in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.","summary":"A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer is a phase 3 interventional study registered as NCT06196736 by Mabwell (Shanghai) Bioscience Co., Ltd., with 432 participants planned, started 2023-12-29 and due to reach its primary completion in 2026-09. Interventions recorded: 9MW2821 and Chemotherapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06196736","url":"https://clinicaltrials.gov/study/NCT06196736"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06196736","phase":"3","setting":"An Open-label, Randomized Phase 3 Study to Evaluate 9MW2821 vs Investigator's Choice of Chemotherapy in Subjects With Locally Advanced or Metastatic Urothelial Cancer Who Have Previously Received PD-(L)1 Inhibitor and Platinum-containing Chemotherapy","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","enrolled":432,"outcomes":[]},"route":"/trials/nct06196736/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}]}}